Releases limited quantities of Cilamin 250 capsules in retail market
Panacea Biotec announced that the Company's brand Cilamin 250 capsules for treatment of Wilsons disease, Rheumatoid Arthritis and other conditions has been made available in limited quantities in the retail market.The temporary shortage is due to sudden disruption of supplies of raw materials by qualified supplier beyond the control of the Company. Due to continuous efforts the Company has resumed limited production of Cilamin 250 and has released limited quantities in the market from 29 September 2016.
The Company expects it would take additional 2-4 weeks for accessing the additional quantities of raw material and additional 4 weeks for Cilamin 250 supplies to normalise.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app